http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3696187-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7112c0cbf5e1742ce9aefc74a6e49fb1 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 |
| filingDate | 2018-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9147e4a28d548a0b67c41937a7c513d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bac22e0087f1457e8d4218428e44789 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b57337eead20fae6260ad8f109684105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b570cffd2122305e01f1d36468a6fdc2 |
| publicationDate | 2020-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3696187-A1 |
| titleOfInvention | Synthetic peptide sp4 and use thereof |
| abstract | Disclosed is a synthetic peptide sp4 with an amino acid sequence shown in SEQ ID No.1. As the sole effective ingredient in the antitumor efficacy test, it has a significant inhibitory effect on both the tumor volume and tumor weight of human osteosarcoma MG-63 in nude mice and has a significant dose-effect and time-effect relationship. There is no difference between the relative tumor growth rate T/C (%) of sp4 and that of the positive control group of Paclitaxel. The safety of sp4 is that its maximal tolerated dose for intravenous administration is 700mg/kgBW. Sp4 has clear targets of pharmacological effects, while having efficacy in vivo, it also has an inhibitory effect on tumor telomerase, has a arrest on G1 phase of the tumor cell cycle, and inhibits the high expressions of tumor PD-L1 and CD47. The present disclosure relates to multiple uses of sp4, especially in the preparation of a class of antitumor drugs. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11482681-B2 |
| priorityDate | 2018-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 81.